* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download X-ray and Cryo-EM Structures for Novel Human Membrane Protein
Model lipid bilayer wikipedia , lookup
Protein (nutrient) wikipedia , lookup
Cell nucleus wikipedia , lookup
Theories of general anaesthetic action wikipedia , lookup
SNARE (protein) wikipedia , lookup
Protein phosphorylation wikipedia , lookup
Cell membrane wikipedia , lookup
G protein–coupled receptor wikipedia , lookup
Magnesium transporter wikipedia , lookup
Circular dichroism wikipedia , lookup
Protein structure prediction wikipedia , lookup
Signal transduction wikipedia , lookup
Protein moonlighting wikipedia , lookup
Endomembrane system wikipedia , lookup
Nuclear magnetic resonance spectroscopy of proteins wikipedia , lookup
Protein mass spectrometry wikipedia , lookup
List of types of proteins wikipedia , lookup
Protein–protein interaction wikipedia , lookup
Intrinsically disordered proteins wikipedia , lookup
X-ray and Cryo-EM Structures for Novel Human Membrane Protein Targets in Diabetes and Obesity Supervisor: Professor Liz Carpenter Department: Structural Genomics Consortium, Nuffield Department of Medicine Background Many genes have been identified as associated with diabetes and obesity through large scale sequencing efforts. A large number of these genes are integral membrane proteins and this class of proteins are regarded as challenging for drug design because they are difficult to produce, assay and obtain structural information. The field of human integral membrane proteins (IMPs) structure and function is however developing rapidly and these targets represent an untapped resource for novel diabetes and obesity targets. Prof. Liz Carpenter’s Integral Membrane Proteins Group at the SGC in Oxford works with a broad range of IMPs, including ion channels, solute carriers, ABC transporters and membrane enzymes. There are potential diabetes targets in all these families. In the past 6 years this group has solved structures of seven human membrane proteins, with examples from each of these families (Quigley et al., Science, 2013; Shintre et al., PNAS, 2013; Dong et al., Science, 2015). We have also developed assays appropriate to each protein, either in house, or through collaborations. Therefore at the SGC, we are uniquely well-placed to produce IMP diabetes targets, solve their structures (by X-ray, serial femtosecond crystallography or cryo-electron microscopy), develop assays and identify probe molecules to study their roles in healthy and patient-derived cells. Novo Nordisk’s programme to study secreted proteins, through protein production, antibodies and peptides as therapeutics, aligns well with our work on plasma membrane proteins, as these proteins are accessible at the surface of cells, and are thus amenable to similar treatments to secreted proteins. Production of integral membrane proteins in proteoliposomes, nanodiscs or detergents for therapeutic purposes would be feasible and would extend the number of diabetes targets that can be studied at the protein level. Aims We aim to: 1. Study novel diabetes and obesity integral membrane protein targets, both targets that are already identified as important for diabetes, and new targets, as further sequencing of genomes leads to the identification of new proteins that are relevant to diabetes. 2. Develop methods for producing of these proteins in a range of formats 3. Work with Novo Nordisk to produce antibodies against these proteins 4. Solve 3D structures of these targets, with antibodies and in complex with small molecule binders. 5. Develop assays for function, stability, small molecule and antibody studies. 6. Design specific probe molecules to activate and inhibit these proteins in cells. Description of work 1. Identify up to 20 human integral membrane proteins that are of interest to Novo Nordisk. Our current target list includes 14 membrane proteins that are associated with diabetes and obesity. We would work with Novo Nordisk scientists to select current targets and identify new targets that are of value for diabetes and obesity. 2. A number of these targets have already been screened for expression in insect cells. The fellow would develop purification protocols for these in parallel with testing new targets for expression, using the SGC’s high-throughput methods. We have screened over 400 IMPs to date and successfully produced 10% of them, so it is essential for the fellow to start with a range of targets. 3. The fellow would develop methods to insert the proteins into proteoliposomes, nanodiscs or lipodiscs. They would then work with Novo Nordisk scientists to determine if these proteins are sufficiently stable to be used as therapeutic agents. Mutagenesis to stabilize the proteins would be an option for proteins of lower stability. 4. Protein in proteoliposomes would be used for antibody production in Novo Nordisk’s labs either by the fellow themselves working in NN labs, or by NN antibody production experts. 5. For the targets that can be produced, the fellow would then use a range of structural biology techniques available in our lab, include X-ray crystallography, serial femtosecond crystallography and electron microscopy to solve the structures of at least one of their targets. 6. For well-behaved targets the fellow would develop assays to assess the function of the protein. We use generic thermostabilization assays to test binding of small molecules to membrane proteins on a medium-throughput scale and then test the effect of compounds using transport assays, electrophysiology assays or enzymatic assays, depending on the type of protein. These assays will be done either in house, with NovoNordisk scientists or through our extensive network of collaborators. These assays can be used to test the effects of stabilization methods, antibodies and peptides on purified protein and protein in membranes. Small molecules can be used to probe the function of proteins in healthy and disease d cells and in animal models. Expected outcomes 1. As integral membrane protein targets are challenging to study, we would expect that within 3 years the fellow would assess the tractability of up to 20 IMP and then focus on five targets that are most likely to give a structure and valuable data for a therapeutic. 2. They would to produce at least three proteins, including developing protocols for producing the protein in proteoliposomes, nanodiscs and lipodiscs. 3. They would use thermostability assays to test stability of preps and to determine whether small molecules, lipids or binding proteins would stabilize the protein. 4. The fellow would aim to solve the structure of at least one of the proteins, using whichever technique is most appropriate for the protein. This work will open up new target areas in the integral membrane proteins field as a collaboration between Novo Nordisk and the SGC. All the research performed in the SGC labs will be published without restriction, once the structures are solved. Recent relevant publications 1. Dong YY, Pike, AC, et al. (2015) K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac. Science 347: 1256-1259. 2. Stansfeld PJ, Goose JE, et al. (2015) MemProtMD: Automated Insertion of Membrane Protein Structures into Explicit Lipid Membranes. Structure 23, 1350-1361. 3. Quigley A, Dong YY, et al. (2013) The structural basis of ZMPSTE24 dependent laminopathies. Science, 339(6127), 1604-1607. 4. Shintre CA, Pike AC et al. (2013) The first human ABC exporter structure reveals the initial steps in the transport cycle. Proc Natl Acad Sci USA, 110, 24: 9710-9715.